Lorlatinib analogs manuscript is published!

Aya, Jess and Satoshi’s manuscript “Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer” is now published in Nature Cancer! This collaboration with the Pfizer lorlatinib team presents specific strategies for targeting different classes of ALK compound resistance mutations.

2022 AACR Annual Meeting

The Hata lab was well represented with two oral presentations at the 2022 AACR Annual Meeting in New Orleans. Hideko Isozaki presented “Impact of therapy induced APOBEC3A mutagenesis on tumor evolution in non small cell lung cancer” highlighting a new mechanism by which targeted therapies may induce mechanisms that facilitate evolution of acquired resistance. Chendi Li presented “LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRAS G12C + MCL-1 blockade,” describing a novel mechanism by which LKB1 loss leads to a targetable therapeutic vulnerability in KRAS mutant lung cancers and providing rationale for clinical testing of KRAS G12C + MCL-1 inhibitors in this patient population.”